52,798 Shares in Zoetis Inc. $ZTS Acquired by Wilson Asset Management International PTY Ltd.

Wilson Asset Management International PTY Ltd. acquired a new stake in Zoetis Inc. (NYSE:ZTS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 52,798 shares of the company’s stock, valued at approximately $8,234,000. Zoetis accounts for about 2.0% of Wilson Asset Management International PTY Ltd.’s portfolio, making the stock its 22nd largest holding.

Other hedge funds also recently modified their holdings of the company. Nova Wealth Management Inc. purchased a new position in shares of Zoetis during the first quarter valued at approximately $25,000. 1248 Management LLC bought a new stake in Zoetis during the first quarter worth $27,000. Saudi Central Bank bought a new stake in Zoetis during the first quarter worth $29,000. Cornerstone Planning Group LLC lifted its holdings in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares during the period. Finally, REAP Financial Group LLC raised its stake in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ZTS shares. Piper Sandler boosted their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Finally, Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $196.71.

Zoetis Stock Performance

Zoetis stock opened at $142.29 on Tuesday. The company has a market capitalization of $63.06 billion, a P/E ratio of 24.49, a PEG ratio of 2.26 and a beta of 0.90. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock’s 50 day moving average is $149.04 and its 200 day moving average is $154.19.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.